<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Navivest Stocks and Options Blog &#187; pfizer</title>
	<atom:link href="http://www.navivest.com/blog/tag/pfizer/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.navivest.com/blog</link>
	<description>Stocks and options trading ideas and market commentary.</description>
	<lastBuildDate>Fri, 23 Jul 2010 17:40:17 +0000</lastBuildDate>
	<meta name="generator" content="Blog 6.4" />
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Medivation Stock Drops 67%</title>
		<link>http://www.navivest.com/blog/2010/03/medivation-stock-drops-67/</link>
		<comments>http://www.navivest.com/blog/2010/03/medivation-stock-drops-67/#comments</comments>
		<pubDate>Thu, 04 Mar 2010 04:09:34 +0000</pubDate>
		<dc:creator>Navivest</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[Stock to watch]]></category>
		<category><![CDATA[dimebon]]></category>
		<category><![CDATA[medivation]]></category>
		<category><![CDATA[pfizer]]></category>

		<guid isPermaLink="false">http://www.navivest.com/blog/?p=104</guid>
		<description><![CDATA[Shares of Medivation (MDVN), sold off rather dramatically today, with the stock dropping from $40.25 to $13.10, a loss of 27.15%, after the company announced that an Alzheimer drug, Dimebon, that it is developing, did not show any “statistically significant improvements” over a placebo group, in a drug study and failed to meet its primary [...]]]></description>
			<content:encoded><![CDATA[<p>Shares of <strong>Medivation</strong> (MDVN), sold off rather dramatically today, with the stock dropping from $40.25 to $13.10, a loss of 27.15%, after the company announced that an Alzheimer drug, Dimebon, that it is developing, did not show any “statistically significant improvements” over a placebo group, in a drug study and failed to meet its primary and secondary endpoints, with those endpoints being “cognition and global function.”</p>
<p>Medivation is developing the drug in partnership with <strong>Pfizer</strong> (PFE), which saw its shares drop 1.59% on the news.</p>
<p>In a press release issued by the company, the company’s CEO, Dr. David Hung, stated that, &#8220;the results from the CONNECTION study are unexpected, and we are disappointed for the Alzheimer&#8217;s community. We are working with our colleagues at Pfizer to better understand the CONNECTION data and we plan to present these data at an upcoming medical meeting.&#8221;</p>
<p>
<!-- Begin Google Adsense code -->
<script type="text/javascript"><!--
google_ad_client = "pub-1936109845292692";
/* 468x60, created 2/21/10 */
google_ad_slot = "1516594150";
google_ad_width = 468;
google_ad_height = 60;
//-->
</script>
<script type="text/javascript"
src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script><!-- End Google Adsense code -->
</p>
]]></content:encoded>
			<wfw:commentRss>http://www.navivest.com/blog/2010/03/medivation-stock-drops-67/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
